Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory DiseasesGlobeNewsWire • 05/15/24
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial ResultsGlobeNewsWire • 05/13/24
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare ConferenceGlobeNewsWire • 05/06/24
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory DiseasesGlobeNewsWire • 03/25/24
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 MillionGlobeNewsWire • 03/12/24
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public OfferingGlobeNewsWire • 03/07/24
Apogee Therapeutics: Success In Phase 1 Bodes Well For Continued APG777 AdvancementSeeking Alpha • 03/06/24
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/05/24
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 DaysGlobeNewsWire • 03/05/24
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024GlobeNewsWire • 03/04/24
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/02/24
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/13/23
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) CongressGlobeNewsWire • 09/27/23
Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee TherapeuticsPRNewsWire • 08/29/23
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/28/23
Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent DosingSeeking Alpha • 08/22/23
Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its BoardGlobeNewsWire • 08/21/23